ClinicalTrials.gg
RecruitingNCT07237750iWAIST-RCTUpdated Oct 26, 2026

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) +Optimized Lifestyle Intervention (OLI) vs Sham + OLI for Weight Loss

An interventional study of Endoscopic Radial Compression Gastroplasty and Optimized Lifestyle Intervention (OLI) in Overweight and/or Obesity, Metabolic Syndrome and Nonalcoholic Fatty Liver Disease, sponsored by Liu Yan. Recruiting at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Liu Yan · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 26, 2026Start date movedPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Metabolic Syndrome with a site in China — 35 open to participants now, 39 under way, 1 of them phase 3. Metabolic Syndrome · China.

Planned enrollment
11th of 50
216 · median 143
Started
2026
with 8 others
No phase
39 of 89
16 open now
Primary completion
2027-03
later than 25 of 38 live
Registered
74th of 89
by date

Among the 89 studies in Metabolic Syndrome with a site in China, this one is the 11th largest by planned enrollment of the 50 interventional ones that give a count, is one of 9 that started in 2026, is one of 39 with no phase, reaches primary completion later than 25 of the 38 other live ones, and was the 74th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

35 of the 89 studies in Metabolic Syndrome with a site in China are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Metabolic Syndrome with a site in China, or all of them as a file.
02

Study summary

This randomized, sham-controlled trial evaluates the efficacy and safety of ERCG plus optimized lifestyle intervention compared with sham procedure plus optimized lifestyle intervention in Chinese adults with overweight accompanied by at least one metabolic comorbidity or with mild-to-moderate obesity. The co-primary outcomes are percentage total weight loss (%TWL) at 12 weeks and the clinical response rate at 12 weeks, defined as the proportion of participants achieving %TWL ≥5%. Secondary outcomes include weight-related, metabolic, hepatic steatosis-related, imaging, symptom, quality-of-life, and safety outcomes.

Read the detailed description

The prevalence of obesity and overweight continues to increase worldwide, and Chinese populations are particularly vulnerable due to lower thresholds for metabolic risk compared with Western populations. Individuals with overweight or mild-to-moderate obesity (BMI 24.0-37.4 kg/m²) often fail conservative measures but are ineligible or unwilling to undergo bariatric surgery because of its invasiveness, risk, and costs. This creates an unmet need for minimally invasive, effective, and scalable interventions.

Endoscopic bariatric and metabolic therapies (EBMTs) have emerged as alternatives, but many existing procedures involve technically complex endoscopic suturing, high costs, or device-related risks. Investigators developed ERCG, a novel endoscopic procedure that reduces gastric volume by apposing the gastric walls using a newly designed clip-and-loop system. Preliminary studies demonstrated that ERCG can induce rapid weight loss, with mean percent total body weight loss (TBWL) of approximately 12% at 3 months, while maintaining a favorable safety profile.

This randomized controlled trial aims to evaluate the efficacy and safety of ERCG compared with an optimized lifestyle intervention (OLI) in Chinese adults with overweight and mild-to-moderate obesity who have failed conservative weight reduction efforts. Eligible participants will be randomized in a 1:1 ratio to ERCG plus optimized lifestyle intervention or sham procedure plus optimized lifestyle intervention. Participants in both groups will undergo the assigned procedure under the same anesthesia strategy and procedural setting. The sham procedure will simulate the duration and peri-procedural experience of ERCG without clip or endoloop placement, gastric wall traction, or gastric volume reduction. Both groups will receive the same optimized lifestyle intervention and follow-up schedule. Follow-up visits are scheduled at 1 month, 2 month, 3 month and 6 month after enrollment.

The primary endpoint is percent TBWL at 3 months, assessed using standardized weight measurement protocols. Secondary endpoints include %EBWL at 3 and 6 months, changes in BMI, metabolic parameters (fasting plasma glucose, HbA1c, insulin resistance indices, lipid profile), quality of life assessed by validated questionnaires (IWQOL-Lite), and the incidence of adverse events classified according to international standards.

Randomization will be computer-generated with concealed allocation, and outcome assessors will be blinded to treatment assignment. Analyses will follow the intention-to-treat principle with appropriate methods for handling missing data.

The study is expected to generate high-quality evidence regarding the short-term and medium-term efficacy of ERCG, to clarify its safety profile, and to determine whether ERCG can serve as a safe and scalable option bridging the therapeutic gap between conservative lifestyle approaches and bariatric surgery for overweight and mildly to moderately obese Chinese populations.

03

Conditions studied

  • Overweight and/or Obesity
  • Metabolic Syndrome
  • Nonalcoholic Fatty Liver Disease

Keywords

  • Endoscopic gastroplasty
  • Endoscopic bariatric therapy
  • Weight loss
  • Overweight
  • Gastric volume reduction
  • Chinese
  • Obesity
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asian adults aged 18-65 years.
  • 24.0-27.9 with ≥ 1 obesity-related complication
  • BMI 28.0-37.4kg/m²
  • Failed prior conservative weight loss attempts
  • Willingness to comply with follow-up.
  • Provided written .

Exclusion criteria

Exclusion Criteria:

  • Prior gastrointestinal surgery with sequelae.
  • Active or clinically significant gastrointestinal disease, including inflammatory conditions (e.g., esophagitis, Barrett's esophagus, Crohn's disease), peptic ulcer disease (gastric/duodenal ulcer), or neoplastic lesions.
  • Any condition associated with an increased risk of upper gastrointestinal bleeding.
  • Hiatal hernia >2 cm or severe/ gastroesophageal reflux disease (GERD); acid reflux requiring ≥2 medications for symptom control.
  • Esophageal/pharyngeal structural abnormalities that may impede endoscope passage (e.g., stricture, diverticulum).
  • Achalasia or other severe esophageal motility disorder.
  • Severe coagulopathy.
  • Insulin-dependent diabetes mellitus.
  • Chronic abdominal pain.
  • Gastrointestinal motility disorder (e.g., gastroparesis).
  • Hepatic impairment or cirrhosis.
  • Severe or uncontrolled psychiatric illness.
  • Alcohol abuse or substance dependence.
  • Unwilling to participate in a physician-supervised diet/behavior modification program and/or unwilling to comply with routine follow-up.
  • Daily regular use of NSAIDs, anticoagulants, or other gastric-irritating medications.
  • Unable or unwilling to take proton pump inhibitor (PPI) therapy as prescribed during the treatment period.
  • Known or suspected to any material/component of the study system.
  • Pregnant or breastfeeding.
  • Severe cardiopulmonary disease or other serious systemic/organic disease.
  • Active infection not successfully eradicated before enrolment.
  • Use of time-critical medications potentially affected by altered gastric emptying (e.g., antiepileptics, antiarrhythmics).
  • Current systemic , , or opioid analgesics.
  • Use of any weight-loss medication within the past 3 months or current use.
  • Prior use of any intragastric device.
  • Participation in a weight-affecting clinical trial within the past 6 months.
  • Symptomatic congestive heart failure, clinically significant arrhythmia, or unstable coronary artery disease.
  • Clinically significant respiratory disease.
  • connective tissue disease.
  • \<1 year or severe renal/hepatic/pulmonary or other serious medical illness.
  • Known genetic or endocrine cause of obesity (e.g., hypothyroidism, Prader-Willi syndrome) or other endocrine disease known to affect body weight.
  • Eating disorder (e.g., night eating syndrome, bulimia nervosa, binge eating disorder, compulsive eating).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
216 participants (estimated)

Study arms

  • Experimental
    ERCG + OLI

    Sutureless endoscopic gastric volume reduction using a clip-and-loop apposition system under non-intubated general anesthesia, plus standardized OLI (dietary counseling, calorie deficit, physical activity prescription, and behavioral support) with visit frequency matched to the comparator.

    Procedure: Endoscopic Radial Compression Gastroplasty · Behavioral: Optimized Lifestyle Intervention (OLI)

  • Sham comparator
    Sham Procedure + OLI

    Participants assigned to the control group will undergo a sham endoscopic procedure under the same anesthesia strategy and procedural setting as the ERCG group. The sham procedure will include routine upper gastrointestinal endoscopy and non-therapeutic maneuvers, such as insufflation, suction, and irrigation, with a total procedure-related duration of approximately 25 minutes. No endoscopic clips or endoloops will be deployed, and no gastric wall traction or gastric volume-reduction procedure will be performed. Participants will subsequently receive the same optimized lifestyle intervention and follow-up schedule as the ERCG group.

    Behavioral: Optimized Lifestyle Intervention (OLI) · Procedure: Sham Endoscopic Procedure

Interventions

  • ProcedureEndoscopic Radial Compression Gastroplasty

    Sutureless endoscopic gastric volume reduction using a novel clip-and-endoloop apposition system; performed under general anesthesia or deep sedation; standard perioperative care.

  • BehavioralOptimized Lifestyle Intervention (OLI)

    Structured nutrition counseling, calorie deficit plan, physical activity prescription per regional guidelines, and behavioral support; visit frequency matched to the ERCG arm.

  • ProcedureSham Endoscopic Procedure

    A sham upper gastrointestinal endoscopic procedure performed under the same anesthesia strategy and procedural setting as ERCG. The procedure includes routine examination of the esophagus, stomach, and duodenum and may include non-therapeutic maneuvers such as insufflation, suction, and irrigation. No clips or endoloops are deployed, and no gastric wall traction or gastric volume-reduction procedure is performed. The total procedure-related duration is approximately 25 minutes.

06

What researchers measure

Primary outcomes

  1. Percent Total Body Weight Loss (%TBWL)

    Percentage total weight loss at 12 weeks will be calculated as: %TWL = \[(baseline body weight - body weight at 12 weeks) / baseline body weight\] × 100%. Body weight will be measured under standardized conditions.

    Time frame: 12 weeks after the assigned procedure

  2. Clinical Responder Rate (CRR)

    The clinical response rate is defined as the proportion of participants achieving %TWL ≥5% at 12 weeks. Percentage total weight loss will be calculated as: %TWL = \[(baseline body weight - body weight at 12 weeks) / baseline body weight\] × 100%.

    Time frame: 12 weeks after the assigned procedure

Secondary outcomes

  1. Body Weight (kg)

    Weight measured on a calibrated scale under standardized conditions (light clothing, no shoes, preferably morning after ≥8h fasting).

    Time frame: Baseline, 3 month, 6month

  2. Body Height (m)

    Standing height measured with a wall-mounted stadiometer, no shoes, heels together, Frankfurt plane horizontal.

    Time frame: Baseline

  3. Percent Excess Body Weight Loss (%EBWL)

    %EBWL is calculated as \[(Baseline weight - Follow-up weight) / (Baseline weight - Ideal weight)\] × 100. Ideal weight is defined as the weight corresponding to a BMI of 23.9 kg/m². Weight is measured using a calibrated scale under standardized fasting conditions at each visit.

    Time frame: 3 and 6 months post-intervention

  4. Change in BMI (kg/m²)

    BMI will be calculated as weight (kg) divided by height squared (m²).

    Time frame: 3 and 6 months post-intervention

  5. Glycated Hemoglobin (HbA1c)

    HbA1c will be measured using standard laboratory methods. Values at each visit and changes from baseline will be summarized.

    Time frame: Baseline, 3 and 6 months

  6. Adverse Events (AEs/SAEs) Related to Procedure

    Number and proportion of participants with device-/procedure-related AEs/SAEs, graded by Clavien-Dindo and per FDA/ISO definitions.

    Time frame: Baseline, 3 and 6 months

  7. GERD-Q Total Score

    Gastroesophageal Reflux Disease Questionnaire (GERD-Q) total score, validated 6-item instrument. Higher scores indicate more severe reflux symptoms.

    Time frame: Baseline, 3, and 6 months

  8. Postoperative Pain (VAS/NRS)

    Patient-reported pain intensity using a 0-10 scale (0=no pain, 10=worst imaginable pain). Assessed at rest.

    Time frame: 6 hours, 24 hours, and 7 days

  9. Postoperative Nausea Score

    Patient-reported nausea severity using a 0-10 numeric rating scale (0=no nausea, 10=worst nausea).

    Time frame: 6 hours, 24 hours, and 7 days

  10. Total Cholesterol

    Total cholesterol will be measured after an overnight fast using standard laboratory methods. Values at each visit and changes from baseline will be summarized.

    Time frame: Baseline, 3 and 6 months

  11. Low-Density Lipoprotein Cholesterol (LDL-C)

    LDL-C will be measured directly or calculated using standard methods. Values at each visit and changes from baseline will be summarized.

    Time frame: Baseline, 3 and 6 months

07

Study locations

1 of 2 sites recruiting
  • The fifth Medical Center of Chinese PLA General Hospital, Beijing
    Beijing, Beijing Municipality 100073, China
    Not yet recruiting
    • Yan Liu, M.D. PH.D. · Contact13911798288@163.com · +8601066947300
    • Yan Liu · Principal investigator
    • Yiyu Qiao · Sub investigator
  • The fifth Medical Center of Chinese PLA General Hospital, Beijing
    Beijing, Beijing Municipality 100073, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 12 months is below that.

Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Dec 2026 → Mar 2027 and completion May 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Nov 20, 2025
StartActual
Mar 13, 2026
Primary completionEst.
Mar 30, 2027was Dec 2026
CompletionEst.
Jun 30, 2027was May 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 1, 2026→Mar 13, 2026
Oct 26, 2026
Primary completion
Dec 30, 2026→Mar 30, 2027
Oct 26, 2026
Study completion
May 31, 2027→Jun 30, 2027
Oct 26, 2026
Eligibility
2 inclusion criteria edited, 1 added; 1 exclusion criterion added, 1 removed
What changed in the criteria
Inclusion criteria
  • AddedBMI 24.0-27.9 with ≥ 1 obesity-related complication
  • EditedBMI 2428.0-37.4kg/m²(Chinese standard)。
  • EditedFailed prior conservative weight loss attempts ≥2 months。
Exclusion criteria
  • RemovedPositive Helicobacter pylori (H. pylori) test.
  • AddedActive infection not successfully eradicated before enrolment.
Oct 26, 2026
Interventions
Added Procedure: Sham Endoscopic Procedure. Arm changed OLI→Sham Procedure + OLI
Oct 26, 2026
Primary outcomes
2 time frame changed, 2 description edited
What changed in the outcomes
  • Time framePercent Total Body Weight Loss (%TBWL)1-6 months post-intervention → 12 weeks after the assigned procedure
  • Time frameClinical Responder Rate (CRR)3 month, 6 month → 12 weeks after the assigned procedure
  • DescriptionClinical Responder Rate (CRR): how it is measured was reworded
  • DescriptionPercent Total Body Weight Loss (%TBWL): how it is measured was reworded
Oct 26, 2026
Secondary outcomes
7 time frame changed
What changed in the outcomes
  • Time frameBody Weight (kg)Baseline, 1 month, 2 month, 3 month, 6month → Baseline, 3 month, 6month
  • Time framePercent Excess Body Weight Loss (%EBWL)1-6 months post-intervention → 3 and 6 months post-intervention
  • Time frameChange in BMI (kg/m²)Baseling, 1 month, 2 months, 3 months and 6 months → 3 and 6 months post-intervention
  • Time frameGlycated Hemoglobin (HbA1c)Baseline, 3 months → Baseline, 3 and 6 months
  • Time frameAdverse Events (AEs/SAEs) Related to Procedure3, 6, 12 months → Baseline, 3 and 6 months
  • Time frameTotal CholesterolBaseline, 3 months → Baseline, 3 and 6 months
  • Time frameLow-Density Lipoprotein Cholesterol (LDL-C)Baseline, 3 months → Baseline, 3 and 6 months
Oct 26, 2026
Title
iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs +Optimized Lifestyle Intervention (OLI) vs Sham + OLI for Weight Loss
Oct 26, 2026
Sponsor
Collaborators added: The General Hospital of Northern Theater Command·Xi'an Central Hospital·The First Affiliated Hospital of Zhengzhou University
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Start date Mar 1, 2026→Mar 13, 2026
    Primary completion Dec 30, 2026→Mar 30, 2027
    Study completion May 31, 2027→Jun 30, 2027
    Eligibility 2 inclusion criteria edited, 1 added; 1 exclusion criterion added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • AddedBMI 24.0-27.9 with ≥ 1 obesity-related complication
    • EditedBMI 2428.0-37.4kg/m²(Chinese standard)。
    • EditedFailed prior conservative weight loss attempts ≥2 months。
    Exclusion criteria
    • RemovedPositive Helicobacter pylori (H. pylori) test.
    • AddedActive infection not successfully eradicated before enrolment.
    Primary outcomes 2 time frame changed, 2 description edited
    What changed in the outcomes
    • Time framePercent Total Body Weight Loss (%TBWL)1-6 months post-intervention → 12 weeks after the assigned procedure
    • Time frameClinical Responder Rate (CRR)3 month, 6 month → 12 weeks after the assigned procedure
    • DescriptionClinical Responder Rate (CRR): how it is measured was reworded
    • DescriptionPercent Total Body Weight Loss (%TBWL): how it is measured was reworded
    Secondary outcomes 7 time frame changed
    What changed in the outcomes
    • Time frameBody Weight (kg)Baseline, 1 month, 2 month, 3 month, 6month → Baseline, 3 month, 6month
    • Time framePercent Excess Body Weight Loss (%EBWL)1-6 months post-intervention → 3 and 6 months post-intervention
    • Time frameChange in BMI (kg/m²)Baseling, 1 month, 2 months, 3 months and 6 months → 3 and 6 months post-intervention
    • Time frameGlycated Hemoglobin (HbA1c)Baseline, 3 months → Baseline, 3 and 6 months
    • Time frameAdverse Events (AEs/SAEs) Related to Procedure3, 6, 12 months → Baseline, 3 and 6 months
    • Time frameTotal CholesterolBaseline, 3 months → Baseline, 3 and 6 months
    • Time frameLow-Density Lipoprotein Cholesterol (LDL-C)Baseline, 3 months → Baseline, 3 and 6 months
    Interventions Added Procedure: Sham Endoscopic Procedure. Arm changed OLI→Sham Procedure + OLI
    Sponsor Collaborators added: The General Hospital of Northern Theater Command·Xi'an Central Hospital·The First Affiliated Hospital of Zhengzhou University
    Title iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs +Optimized Lifestyle Intervention (OLI) vs Sham + OLI for Weight Loss
    + 4 other changes: verification date, description, conditions and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07237750
Lead sponsor
Liu Yan
Collaborators
Wuhan TongJi Hospital, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Ankang City Central Hospital, The First Affiliated Hospital of Soochow University, LanZhou University, The General Hospital of Northern Theater Command, Xi'an Central Hospital, The First Affiliated Hospital of Zhengzhou University
Responsible party
Liu Yan (Director and Chief Physician, Department of Gastroenterology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 302 Hospital) — Sponsor-investigator
First posted
Nov 20, 2025
Start date
Mar 13, 2026
Primary completion
Mar 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Yan Liu, M.D. PH.D.
Contact
13911798288@163.com
+8601066947300
Yiyu Qiao, M.D. PH.D.
Contact
qyy96@126.com
+8601066947300

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion